Rituximab for the treatment of extranodal marginal zone B-cell lymphoma of the lacrimal gland
- Carsten Heinz1,
- Hartmut Merz2,
- Matthias Nieschalk3,
- Heribert Mueller-Miny4,
- Peter Koch5,
- Arnd Heiligenhaus6
- 1Department of Ophthalmology, St. Franziskus-Hospital Muenster, Muenster, Germany and Department of Ophthalmology, University of Duisburg-Essen, Duisburg, Germany
- 2Department of Pathology, University of Schleswig-Holstein, Luebeck, Germany
- 3Department of ENT, St. Franziskus-Hospital Muenster, Muenster, Germany
- 4Department of Radiology, St. Franziskus-Hospital Muenster, Muenster, Germany
- 5Department of Medicine Haematology/Oncology, University of Muenster, Muenster, Germany
- 6Department of Ophthalmology, St. Franziskus-Hospital Muenster, Muenster, Germany and Department of Ophthalmology, University of Duisburg-Essen, Duisburg, Germany
- Dr Carsten Heinz, Department of Ophthalmology, St. Franziskus-Hospital Muenster, Hohenzollernring 54, 48145 Muenster, Germany; carsten.heinz{at}uveitis-zentrum.de
- Accepted 30 January 2007
Extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma) of the lacrimal gland is a rare condition. Treatment options chiefly include radiation of the tumour, chemotherapy, surgical removal or a combination of these strategies.1 Radiation therapy is associated with a high risk of ocular morbidity, especially dry eye.1 Here, we report a case of a biopsy-proven extranodal MALT lymphoma of the lacrimal gland treated with two courses of four weekly cycles of rituximab.
Case report
A 64-year-old woman presented with unilateral ptosis and swelling of her right lacrimal gland. Best-corrected visual acuity was 20/25. Slit-lamp examination showed severe punctate superficial keratopathy (basal secretion 0 mm OU). …








